Syno Capital

Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. It uses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs.

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. It uses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs.

Honor is the world’s largest senior care network and technology platform. They are fundamentally changing the way we care for parents and loved ones by helping improve the quality of life for more older adults, their families, our Care Professionals, and home care agency owners. In 2021, Honor acquired Home Instead. Honor’s technology and operations platform, paired with Home Instead’s global network and relationship-based care, enables the combined company to solve how we care for aging adults and professional caregivers around the world. In 2014, Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg co-founded the company in San Francisco, California.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

LungLife AI is a molecular diagnostics company that involves in the early detection and treatment of cancer. It uses machine learning and artificial intelligence to enable life-saving early diagnosis of lung cancer. The company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled the molecular analysis of cancer biomarkers in blood. The company is developing tests that span all stages of lung cancer from aid in diagnosis for patients with early-stage disease to treatment stratification and monitoring in late-stage lung cancer. The company's diagnostic technology combined with machine learning and image analysis results in workflow efficiencies and improvement in performance. It was founded in 2008 and is headquartered in Thousand Oaks, California.